The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β-secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β-amyloid aggregates.Jedinjenje predstavljeno strukturnom formulom izabranom između:ili njegova farmaceutski prihvatljiva so.Prijava sadrži još 13 patentnih zahteva.